1. Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation

   • Joanna C. Thorn
   • Joanna Coast
   • Dyfrig Hughes

   Current Opinion 26 March 2013 Pages: 155 - 161

   

2. Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making?

   • Axel C. Mühlbacher
   • Christin Juhnke

   Review Article 26 March 2013 Pages: 163 - 180

3. Cost Effectiveness of Fecal DNA Screening for Colorectal Cancer: A Systematic Review and Quality Appraisal of the Literature

   • Mairead Skally
   • Paul Hanly
   • Linda Sharp

   Systematic Review 03 April 2013 Pages: 181 - 192

   

4. Time Costs Associated with Informal Care for Colorectal Cancer: An Investigation of the Impact of Alternative Valuation Methods

   • Paul Hanly
   • Alan Ó. Céilleachair
   • Linda Sharp

   Original Research Article 03 April 2013 Pages: 193 - 203

   

5. Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France

   • Sylvain Pichetti
   • Catherine Sermet
   • Lars L. Gustafsson

   Original Research Article 23 April 2013 Pages: 205 - 218

   

6. Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective

   • Ronald C. Wielage
   • Megha Bansal
   • Michael Happich

   Original Research Article 25 April 2013 Pages: 219 - 236

   

7. Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome

   • Stefan Kaspers
   • Michael B. Ranke
   • Joris Kleintjens

   Original Research Article Open access 07 May 2013 Pages: 237 - 249

   

8. Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years

   • Reiko Sato
   • Gabriel Gomez Rey
   • Brett Pinsky

   Original Research Article Open access 20 April 2013 Pages: 251 - 258

   

9. A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use

   • David Price
   • Yumi Asukai
   • Ian Keyzor

   Original Research Article Open access 26 March 2013 Pages: 259 - 274

   

10. Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs

    • Juliana Meyers
    • Yanni Yu
    • Keith L. Davis

    Original Research Article 16 May 2013 Pages: 275 - 286

    

11. A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States

    • Richard Norman
    • Paula Cronin
    • Rosalie Viney

    Original Research Article 07 May 2013 Pages: 287 - 298

    

12. Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective

    • Vijay N. Joish
    • Monica Spilsbury-Cantalupo
    • Susan Boklage

    Original Research Article 12 April 2013 Pages: 299 - 304

    

13. Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

    • Carlos I. Alatorre
    • Virginia Haynes
    • Douglas Kelsey

    Correspondence 29 March 2013 Pages: 305 - 305

14. Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”

    • M. Haim Erder
    • Jipan Xie
    • Vanja Sikirica

    Correspondence Open access 17 April 2013 Pages: 307 - 307

15. Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

    • M. Haim Erder
    • Jipan Xie
    • Vanja Sikirica

    Erratum 21 March 2013 Pages: 309 - 309